ArticleInternational journal of general medicine2026
Identification and Validation of RORC as a Circadian Rhythm-Related Biomarker in Gastric Cancer.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Gastric cancer (GC) represents a malignant neoplasm with high global incidence and mortality rates. The limited efficacy of current clinical treatment regimens underscores the urgent need for novel and more effective therapeutic targets. Patients and Methods: Through the utilization of public databases, we identified circadian rhythm genes associated with GC and conducted an analysis of their expression profiles. Enrichment analysis was performed using the KEGG/GO pathways via the "clusterProfiler" package, immune correlation was assessed through ssGSEA (GSVA), tumor mutations were analyzed using TCGA somatic data, and drug sensitivity was evaluated using the "pRRophetic" package. The biological functions of RORC in GC cells were investigated through CCK8, colony formation, and Transwell assays. Results: RORC has been identified as a pivotal gene associated with circadian modulation in gastric cancer. Its expression is markedly reduced in gastric cancer tissues compared to adjacent normal tissues. Enrichment analysis indicates a significant correlation between RORC and the regulation of circadian rhythms. Immunocorrelation analysis demonstrates a significant association between RORC gene expression and T follicular helper cells (Tfh), T cell co-stimulation, and activated dendritic cells (aDCs). Analysis of mutations related to the RORC gene reveals that missense mutations are the predominant type. Notably, key genes such as TP53 and ARID1A show relatively high mutation frequencies in both high and low RORC expression groups. Drug sensitivity analysis indicates that the RORC gene is responsive to agents such as VX-680, MG-132, and Sunitinib. Cell biology experiments have confirmed that RORC overexpression significantly diminishes the proliferation, invasion, and migration capabilities of gastric cancer cells. Conclusion: Integrating bioinformatics and cell biology experiments suggests that RORC, a gene associated with rhythm regulation, acts as a tumor suppressor gene that is underexpressed in gastric cancer, thereby serving as a potential biomarker and therapeutic target for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.